Search research articles
Contact Us
Filters
Showing results (61-70 of 64) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 64 results.
Frontiers in Immunology
|
August 29, 2024
IgA vasculitis induced by carboplatin + nab-paclitaxel + pembrolizumab in a patient with advanced lung squamous cell carcinoma: a case report
Yuto Terashima, Masaru Matsumoto, Saeko Ozaki, et al.
Cancer Science
|
November 30, 2021
Alpha-actinin-4 (ACTN4) gene amplification is a predictive biomarker for adjuvant chemotherapy with tegafur/uracil in stage I lung adenocarcinomas
Rintaro Noro, Kazufumi Honda, Kengo Nagashima, et al.
International Journal of Clinical Oncology
|
October 13, 2021
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)
Yukari Tsubata, Kana Watanabe, Ryota Saito, et al.
International Journal of Clinical Oncology
|
March 8, 2022
Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B)
Yukari Tsubata, Kana Watanabe, Ryota Saito, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 64) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 64 results.
Frontiers in Immunology
|
August 29, 2024
IgA vasculitis induced by carboplatin + nab-paclitaxel + pembrolizumab in a patient with advanced lung squamous cell carcinoma: a case report
Yuto Terashima, Masaru Matsumoto, Saeko Ozaki, et al.
Cancer Science
|
November 30, 2021
Alpha-actinin-4 (ACTN4) gene amplification is a predictive biomarker for adjuvant chemotherapy with tegafur/uracil in stage I lung adenocarcinomas
Rintaro Noro, Kazufumi Honda, Kengo Nagashima, et al.
International Journal of Clinical Oncology
|
October 13, 2021
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)
Yukari Tsubata, Kana Watanabe, Ryota Saito, et al.
International Journal of Clinical Oncology
|
March 8, 2022
Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B)
Yukari Tsubata, Kana Watanabe, Ryota Saito, et al.
Page
of 7